AB Science announces that results from masitinib study AB07015 in severe asthma have been …

Paris, 13 October 2020, 6pm

Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on 16th October, 2020

AB Science SA (Euronext – FR0010557264 – AB) today announced that results from masitinib study AB07015 in severe asthma have been selected for presentation at an upcoming American Thoracic Society (ATS) symposium.

The ATS Allergy, Immunology, and Inflammation Assembly will host a virtual symposium on October 16, 2020 at 10 am (Eastern Standard Time). This is a chaired virtual meeting during which selected abstracts from the ATS 2020 International Conference (ATS 2020 Virtual) are presented live with questions from moderators and audience.  

Pascal Chanez, Professor of Respiratory Diseases at Aix-Marseille University, France, will present the results of masitinib as a treatment of severe corticosteroid-dependent asthma.

Details for the presentation are as follows:

Session Title:                  Late Breaking Clinical Trials in Airway Diseases
Date

Read More
Read More